Recent American Society of Breast Surgeons (ASBrS) Guidelines are Favorable to Next Generation Cryoablation Developer, IceCure Medical
Plans to Increase Presence at Global Interventional Oncology (IO) Medical Conferences
CAESAREA, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Following the American Society of Breast Surgeons (ASBrS) Guideline, which were announced in October 2018, IceCure Medical Ltd (TASE: ICCM) plans to increase its presence at Interventional Oncology (IO) conferences. This will further raise the awareness and benefits of its next generation cryoablation technology, ProSenseTM, for women’s health.
The ProSense™ nitrogen-liquid based system enables rapid minimally-invasive, safe, and effective treatment of tumors.
IceCure’s technology provides physicians with full control over the procedure, ensuring that the treated zone is destroyed completely while leaving surrounding tissue undamaged. IceCure has received US Food and Drug Administration (FDA) 510k and CE Mark approvals for its minimally-invasive cryoablation applications.
“Following the outstanding clinical results from our landmark ICE3 clinical trial treating breast cancers, we believe IceCure’s ProSense system will help set new standards in providing minimally-invasive tumor therapy to the interventional oncology market,” said IceCure Medical CEO, Eyal Shamir.
The Company believes the ASBrS guidelines are favorable to its medical field and targets a sizeable unmet medical need in women’s health, oncology intervention radiology. To read the complete statement from the ASBrS, please use this link: https://www.breastsurgeons.org/about/statements/PDF_Statements/Transcutaneous_Percutaneous.pdf
For a full demo of the system, IceCure will be attending the upcoming Interventional Oncology Conferences.
- European Conference on Interventional Oncology (ECIO) annual meeting will take place from April 8-11 in Amsterdam, the Netherlands.
- American Society of Breast Surgeons (ASBrS) annual meeting will take place April 30-May 5 in Dallas, Texas.
- Society of Interventional Oncology (SIO) annual meeting will take place from June 8-11 in Boston, MA.
If you would like to schedule a meeting with management at these conferences, please contact Michael Polyviou at EVC Group at firstname.lastname@example.org or by phone at 732-933-2754.
About IceCure Medical
Founded in 2006, Israel-based IceCure Medical (TASE: ICCM), develops and markets minimally invasive cryoablation therapies for women’s health and Interventional oncology market, with the primary focus areas being breast, kidney and lung cancer. The Company’s Cryoablation therapies, such as its proprietary ProSense™ liquid-nitrogen based system, is safe, innovative and provides clinical and economic benefits compared to the current standard of care.
Released February 5, 2019